Orexigen buys U.S. rights to obesity drug from Takeda

(Reuters) - Orexigen Therapeutics Inc said it would pay $60 million to acquire the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co.

http://ift.tt/1YV7YHK

from Reuters: Health News
via animenewspro